TipRanks
VSee Health (VSEED)
OTHER OTC:VSEED
US Market
Want to see VSEED full AI Analyst Report?

VSee Health (VSEED) AI Stock Analysis

234 Followers

Top Page

VSEED

VSee Health

(OTC:VSEED)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - Gpt-5.6Sol)
Rating:44Neutral
Price Target:
$2.00
▲(9900.00% Upside)
Action:Reiterated
Date:10/01/26
The score is mainly held back by weak financial performance—declining revenue, very large losses, and sustained negative operating/free cash flow—despite manageable current leverage. Technicals also weigh on the score with the price below key moving averages and a negative MACD. Valuation is only modestly supportive because negative earnings make the P/E difficult to rely on and no dividend yield is available.
Positive Factors
Recurring software and RPM revenue model
Recurring SaaS subscriptions, RPM program revenue, enterprise contracts, and implementation services give VSee Health multiple repeatable revenue channels. This model can deepen customer workflows over time and create a foundation for durable revenue if provider and organization usage expands.
Negative Factors
Revenue contraction
The recent reversal from prior growth to a 12.6% TTM revenue decline indicates that demand or monetization has not yet demonstrated durable momentum. A shrinking revenue base makes it harder to absorb fixed costs, fund product development, and reach operating scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring software and RPM revenue model
Recurring SaaS subscriptions, RPM program revenue, enterprise contracts, and implementation services give VSee Health multiple repeatable revenue channels. This model can deepen customer workflows over time and create a foundation for durable revenue if provider and organization usage expands.
Read all positive factors

VSee Health (VSEED) vs. SPDR S&P 500 ETF (SPY)

VSee Health Business Overview & Revenue Model

Company Description
VSee Health, Inc. specializes in delivering virtual healthcare solutions. Their flagship offering, iDoc Telehealth, is specifically designed to manage and coordinate comprehensive care for severely ill individuals within various critical care envi...
How the Company Makes Money
VSee Health primarily makes money by selling access to its telehealth and RPM software as recurring subscriptions and enterprise contracts. Revenue is typically generated through: (1) software licensing / SaaS fees for use of its HIPAA-compliant v...

VSee Health Financial Statement Overview

Summary
Financials are pressured by contracting TTM revenue (~$12.6M, down ~12.6%) and very weak profitability (net margin around -110%) alongside persistent cash burn (TTM operating and free cash flow both about -$5.2M). The balance sheet is less concerning near-term with modest debt (~$1.9M) and moderate leverage (debt-to-equity ~0.25), but ongoing losses keep overall financial quality weak.
Income Statement
23
Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

VSee Health Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.02
Price Trends
50DMA
2.72
Negative
100DMA
6.94
Negative
200DMA
16.31
Negative
Market Momentum
MACD
-0.21
Negative
RSI
54.79
Neutral
STOCH
34.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VSEED, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 1.42, below the 50-day MA of 2.72, and below the 200-day MA of 16.31, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 54.79 is Neutral, neither overbought nor oversold. The STOCH value of 34.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VSEED.

VSee Health Risk Analysis

VSee Health disclosed 62 risk factors in its most recent earnings report. VSee Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

VSee Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
$218.05M-2.60-33.27%―-19.00%40.98%
52
Neutral
$1.03B-5.58-13.08%―-2.08%16.88%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
44
Neutral
$1.49M-0.07-400.87%―-9.31%89.42%
43
Neutral
$15.56M-0.01-32.44%―-28.30%-86.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VSEED
VSee Health
1.98
-49.06
-96.12%
TDOC
Teladoc
5.52
-3.49
-38.73%
ZCMD
Zhongchao
1.85
-1,858.15
-99.90%
AMWL
American Well
12.39
6.06
95.73%
ONMD
OneMedNet
5.39
-4.91
-47.66%
EUDA
EUDA Health Holdings
17.24
-27.36
-61.35%

VSee Health Corporate Events

Private Placements and FinancingRegulatory Filings and Compliance
VSee Health Pursues Private Note and Equity Financing
Neutral
Sep 30, 2026
VSee Health disclosed that it will issue an Additional Vanquish Note, along with shares of common stock issuable upon conversion of the note, in a private transaction exempt from registration under the Securities Act of 1933 and Regulation D. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 01, 2026